Physician profile
Eran L Sykes
NPI 1306187711
$5,737.46
in general payments reported to CMS, 2019-2025
24 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 90% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $973 · 2023: $1,627 · 2024: $1,385 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,308 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.79 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $683.50 | 2021-2025 | |
| Genzyme Corporation | $658.82 | 2021-2025 | |
| Lilly USA, LLC | $595.11 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $578.76 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $491.85 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $404.84 | 2022-2025 | Sotyktu |
| Incyte Corporation | $335.89 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $286.00 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $230.47 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $218.17 | 2021-2024 | Winlevi, Absorica Ld |
| Amgen INC. | $203.24 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $199.26 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $180.59 | 2023-2025 | Nemluvio |
| Leo Pharma INC. | $174.78 | 2021-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $131.66 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.67 | 2022-2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $60.55 | 2024-2025 | Ycanth |
| Ucb, INC. | $54.60 | 2024 | Bimzelx |
| Journey Medical Corporation | $43.90 | 2022-2023 | |
| Organon LLC | $23.38 | 2025 | Vtama |
| Almirall LLC | $19.56 | 2024 | Klisyri |
| Epi Health, LLC | $15.05 | 2022 | |
| Lnhc, INC | $13.62 | 2025 | Zelsuvmi |
| Mission Pharmacal Company | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eran Sykes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.